The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

Tue, 13th Jul 2021 11:20

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Evgen Pharma, up 13% at 5.29 pence, 12-month range 4.22p-16p. The drug development company reported filing of an orphan drug designation request with the US Food & Drug Administration for use of SFX-01 to treat malignant glioma. In parallel, an investigational new drug dossier is being prepared for submission to the US regulator around the end of the year, to support a phase II trial in glioma/glioblastoma that is being planned for commencement in the first half of 2022.

----------

Star Phoenix Group, up 12% at 1.58 pence, 12-month range 1.20p-4.10p. The investment company said it has signed a non-binding agreement with a national university in Australia, Curtin University, to jointly explore, appraise and develop natural hydrogen opportunities in Western Australia. Both parties would undertake an initial low-cost work programme over two years from execution of agreement. The aim would be to appraise natural hydrogen production points in Western Australia, specifically in areas having a high iron-rich content and circular depressions.

----------

Ebiquity, up 6.5% at 56.45 pence, 12-month range 17.10p-58.97p. The media investment analysis firm said trading in the first half of 2021 was in line with expectations. Ebiquity's business continued to build on the momentum of the second half of 2020 with revenue of GBP32 million, 19% ahead of the previous year. This reflected both the recovery in demand from existing clients as they returned to "more normal" activity levels, and success in winning new business.

----------

Redde Northgate up 5.1% at 450.00 pence, 12-month range 158p-157.50p. The mobility solutions platform completed a deal to acquire Charged Electric Vehicles, a supplier of electric vehicle charging equipment in the UK. Redde did not disclose the value of the acquisition. It completed the buy on July 9. Redde said the deal will allow it to expand in the growing electric vehicle market. It will also support its own electric vehicle fleet, the Darlington, England-based firm said.

----------

AIM - LOSERS

----------

Victoria Oil & Gas, down 20% at 4.22p, 12-month range 1.85p-8.15p. The domestic energy supplier said pretax loss in 2020 narrowed to USD8.8 million from USD112.0 million the year before, as it did not record any impairment charges versus USD95.9 million in 2019. Revenue, meanwhile, declined to USD13.2 million from USD20.8 million year-on-year.

----------

DP Poland, down 11% at 7.60 pence, 12-month range 7.0p-11p. The franchise in Poland for Domino's Pizza posted average daily dine-in sales for the period from May 18 to June 30 of PLN122,900 - about GBP22,962 - and increase of 94% in comparison to the lockdown period from May 1 to May 17, when its sales were PLN63,300. Like-for-like system sales for June were 5% higher in comparison to June 2020 and 2% lower compared to June 2019.

----------

Solid State, down 6.8% at 932.50 pence, 12-month range 534p-1,065p. The electronics company reports revenue slip to GBP66.3 million in the financial year to March 31 from GBP67.4 million posted the year before. Pretax profit meanwhile rose by 5% to GBP4.2 million year-on-year. Solid State said its performance reflects diversified market sector exposure which has given the business resilience to the Covid-19 pandemic and Brexit challenges. The company upped its dividend for the year by 28% to 16.0p per share.

----------

Oracle Power, down 5.9% at 0.45, 12-month range 0.4p-0.89p. The coal resource developer said activity has intensified over the past three months at its two gold projects in Western Australia. Looking in the more immediate future, the company said drilling is anticipated to start at Northern Zone, "in a matter of weeks".

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.